Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC lifted its position in Fortress Biotech, Inc. (NASDAQ:FBIO) by 19.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 81,300 shares of the biopharmaceutical company’s stock after purchasing an additional 13,000 shares during the quarter. 180 Wealth Advisors LLC owned approximately 0.29% of Fortress Biotech worth $165,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC boosted its position in shares of Fortress Biotech by 28.8% in the 3rd quarter. Geode Capital Management LLC now owns 168,607 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 37,736 shares during the period. PVG Asset Management Corp acquired a new stake in shares of Fortress Biotech in the 2nd quarter valued at about $266,000. Atria Investments Inc boosted its position in shares of Fortress Biotech by 58.4% in the 3rd quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 26,351 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of Fortress Biotech by 68.2% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 46,100 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 18,700 shares during the period. Finally, Shikiar Asset Management Inc. boosted its position in shares of Fortress Biotech by 4.4% in the 3rd quarter. Shikiar Asset Management Inc. now owns 235,969 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 10,000 shares during the period. 96.51% of the stock is owned by institutional investors and hedge funds.

Fortress Biotech Trading Down 0.8 %

Fortress Biotech stock opened at $1.88 on Thursday. Fortress Biotech, Inc. has a twelve month low of $1.36 and a twelve month high of $2.89. The stock has a 50 day moving average of $1.91 and a two-hundred day moving average of $1.87. The stock has a market capitalization of $51.90 million, a price-to-earnings ratio of -0.62 and a beta of 1.67.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. HC Wainwright upped their target price on Fortress Biotech from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, November 18th. StockNews.com cut Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, Fortress Biotech currently has an average rating of “Moderate Buy” and a consensus price target of $13.67.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.